{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:44:02Z","timestamp":1791380642605,"version":"4.3.3"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jsat.2021.108283","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T02:17:49Z","timestamp":1611109069000},"page":"108283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island"],"prefix":"10.1016","volume":"124","author":[{"given":"Seth A.","family":"Clark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel S.","family":"Wightman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Wunsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee Ann Jordison","family":"Keeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Samuels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2021.108283_bb0005","doi-asserted-by":"crossref","DOI":"10.7326\/M20-1141","article-title":"An epidemic in the midst of a pandemic: Opioid use disorder and COVID-19","author":"Alexander","year":"2020","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jsat.2021.108283_bb0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jsat.2018.07.006","article-title":"Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington","volume":"93","author":"Amiri","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.jsat.2021.108283_bb0015","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jrh.12307","article-title":"Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5-year update","volume":"35","author":"Andrilla","year":"2019","journal-title":"Journal of Rural Health"},{"key":"10.1016\/j.jsat.2021.108283_bb0020","doi-asserted-by":"crossref","DOI":"10.7326\/M20-1210","article-title":"When epidemics collide: Coronavirus disease 2019 (COVID-19) and the opioid crisis","author":"Becker","year":"2020","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jsat.2021.108283_bb0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.drugalcdep.2018.09.007","article-title":"Understanding the use of diverted buprenorphine","volume":"193","author":"Cicero","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108283_bb8000","article-title":"Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19","author":"Davis","year":"2020","journal-title":"The International journal on drug policy, 102905"},{"key":"10.1016\/j.jsat.2021.108283_bb0030","author":"Drug Enforcement Administration"},{"key":"10.1016\/j.jsat.2021.108283_bb0035","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.drugalcdep.2017.01.048","article-title":"The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting","volume":"176","author":"Eibl","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.jsat.2021.108283_bb0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3711","article-title":"Association of racial\/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States","volume":"3","author":"Goedel","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.jsat.2021.108283_bb0045","series-title":"Geographic disparities affect access to buprenorphine services for opioid use disorder","author":"Grimm","year":"2020"},{"issue":"2","key":"10.1016\/j.jsat.2021.108283_bb0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","article-title":"Defining low-threshold buprenorphine treatment","volume":"14","author":"Jakubowski","year":"2020","journal-title":"Journal of Addiction Medicine"},{"issue":"8","key":"10.1016\/j.jsat.2021.108283_bb0055","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment","volume":"105","author":"Jones","year":"2015","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.jsat.2021.108283_bb0060","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.drugalcdep.2018.12.030","article-title":"Co-occurring substance use and mental disorders among adults with opioid use disorder","volume":"197","author":"Jones","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.jsat.2021.108283_bb0065","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","article-title":"American Society of Addiction Medicine (ASAM) National practice guideline for the use of medications in the treatment of addiction involving opioid use","volume":"9","author":"Kampman","year":"2015","journal-title":"Journal of Addiction Medicine"},{"issue":"9","key":"10.1016\/j.jsat.2021.108283_bb0070","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine treatment divide by race\/ethnicity and payment","volume":"76","author":"Lagisetty","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jsat.2021.108283_bb9000","series-title":"Telehealth Response for E-prescribing Addiction Therapy Services Act of 2020","year":"2020"},{"key":"10.1016\/j.jsat.2021.108283_bb0075","series-title":"Medications for opioid use disorder save lives","author":"National Academies of Sciences, E., and Medicine","year":"2019"},{"key":"10.1016\/j.jsat.2021.108283_bb0080","unstructured":"Ryan Haight Online Pharmacy Consumer Protection Act of 2008, H.R. 6353 C.F.R. (2008)."},{"key":"10.1016\/j.jsat.2021.108283_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.09.003","article-title":"Patient experiences with a transitional, low-threshold clinic for the treatment of substance use disorder: A qualitative study of a bridge clinic","volume":"107","author":"Snow","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108283_bb0090","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1016\/j.jsat.2021.108283_bb0095","author":"Substance Abuse and Mental Health Services Administration"},{"key":"10.1016\/j.jsat.2021.108283_bb0100","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.3940","article-title":"Treating patients with opioid use disorder in their homes: An emerging treatment model","author":"Uscher-Pines","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jsat.2021.108283_bb0105","doi-asserted-by":"crossref","DOI":"10.7326\/M20-1212","article-title":"Collision of the COVID-19 and addiction epidemics","author":"Volkow","year":"2020","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1016\/j.jsat.2021.108283_bb0110","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/ADM.0000000000000287","article-title":"Treatment Outcome Comparison Between Telepsychiatry and Face-to-face Buprenorphine Medication-assisted Treatment for Opioid Use Disorder: A 2-Year Retrospective Data Analysis","volume":"11","author":"Zheng","year":"2017","journal-title":"Journal of addiction medicine"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074054722100009X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074054722100009X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:53:57Z","timestamp":1760039637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074054722100009X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":24,"alternative-id":["S074054722100009X"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108283","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108283"}}